Enduring Material

Treating Psoriasis with Phototherapy
View Activity Info
Enter Basic User Info
View Content
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

1800 Diagonal Road, Suite 360
Alexandria, VA 22314
General Information
Wednesday, January 12, 2022 - Friday, January 12, 2024
30 minutes
National Psoriasis Foundation
Virtual Conference Room
Psound Bytes CME Podcast
National Psoriasis Foundation
Objectives
  • Have a better understanding of using phototherapy to manage psoriasis
Presentations and Speakers
Treating Psoriasis with Phototherapy
  • Joel Gelfand, MD
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.5 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Hear Dr. Joel Gelfand, Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit and Director, Psoriasis and Phototherapy Treatment Center, discuss the use of phototherapy as a treatment for psoriasis and give us an update on the LITE Study.

This program is supported by educational grants from AbbVie, Novartis, Pfizer and UCB.
Disclosure Statements
NPF Staff/Planning Committee, has disclosed no relevant financial relationships with commercial interests.
Speakers:
Joel Gelfand, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Abbvie, BMS, Boehringer Ingelheim, Celldex, FIDE, GSK, Happify, Lilly , Leo, Janssen Biologics, Neumentum, Novartis Corp, Pfizer, UCB, Neuroderm, Regeneron, Trevi, and Mindera DX - Consulting - Relationship Has Not Ended
  • Boehringer Ingelheim, and Pfizer Inc - Contracted Research - Relationship Has Not Ended
  • resiquimod - co-patent holder - Relationship Has Not Ended

Support for this activity is gratefully acknowledged from Amgen. Support for this activity is gratefully acknowledged from Novartis. Support for this activity is gratefully acknowledged from Pfizer. Support for this activity is gratefully acknowledged from UCB.
Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
0 %
100 %
1/12/2022
Continue to Enduring Material